Hermetica Superfood Encyclopedia
The Short Answer
Erythrina lysistemon bark contains prenylated isoflavonoids, pterocarpans, and flavans — notably erybraedin A and eryzerin C — that disrupt bacterial cell membranes and inhibit microbial growth through structure-dependent mechanisms enhanced by prenylation and specific hydroxyl group positioning. Erybraedin A demonstrates potent in vitro antibacterial activity with a minimum inhibitory concentration of 2 μg/mL against Staphylococcus aureus and S. epidermidis, while eryzerin C, first isolated from this species, inhibits Escherichia coli at an MIC of 5 μg/mL.
CategoryHerb
GroupAfrican
Evidence LevelPreliminary
Primary KeywordIsihlahla Erythrina lysistemon benefits
Isihlahla — botanical close-up
Health Benefits
**Antibacterial Activity**
Prenylated pterocarpan erybraedin A exhibits an MIC of 2 μg/mL against Gram-positive pathogens S. aureus and S. epidermidis in vitro, with the prenyl group and hydroxyl substituents at rings A and B shown to be critical structural determinants of potency.
**Anti-inflammatory and Analgesic Effects**
Traditional use for pain and inflammation is supported by the presence of isoflavonoids and flavans known to modulate inflammatory pathways in related species; however, direct mechanistic data for E. lysistemon remain derived primarily from ethnobotanical reports and preliminary extracts.
**Antidiabetic Potential**
Crude bark extracts have demonstrated restoration of serum insulin levels, improvement of HDL cholesterol, reduction of glycosylated hemoglobin, and protection of pancreatic islet cells in preliminary in vivo animal models, suggesting beta-cell-protective and insulin-sensitizing properties.
**Antiviral (HIV) Activity**
Isolated compounds 5-deoxyglyasperin F and 2′-hydroxyneobavaisoflavanone show in vitro anti-HIV activity with EC50 values of 11.5 μg/mL and 7.6 μg/mL respectively, indicating isoflavanone scaffolds from this species as candidates for antiviral drug discovery.
**Antiplasmodial Properties**
Related Erythrina-class compounds erythrabbysin II (IC50 5.5 μg/mL), soyaspongenol B (IC50 4.6 μg/mL), and erystagallin A (IC50 3.8 μg/mL) demonstrate in vitro antimalarial activity, supporting the traditional southern African use of Erythrina species for febrile illness.
**Anticancer Research Interest**
The pterocarpan cristacarpin, identified in related Erythrina species and structurally present in E. lysistemon extracts, has been associated with selective inhibition of DNA damage repair pathways in cancer cell lines, representing a preliminary mechanistic rationale for anticancer screening.
**Antimicrobial Broadening Against Gram-Negative Bacteria**: Lysisteisoflavone
an isoflavonoid named for this species — inhibits E. coli at an MIC of 6 μg/mL, while phaseollidin achieves an MIC of 20 μg/mL against E. coli, extending the antimicrobial relevance beyond Gram-positive organisms typically sensitive to flavonoid-class compounds.
Origin & History
Natural habitat
Erythrina lysistemon is a deciduous tree native to southern and eastern Africa, particularly abundant in South Africa, Zimbabwe, Mozambique, and Swaziland, where it thrives in bushveld, woodland margins, and rocky hillsides at low to mid altitudes. It is widely cultivated as an ornamental street and garden tree across subtropical Africa due to its striking scarlet flowers, which appear before new leaves in spring. The tree, commonly called the Common Coral Tree, grows in well-drained soils with seasonal rainfall and is not typically cultivated for medicinal commercial purposes, with most traditional use relying on wild-harvested bark and seeds.
“Erythrina lysistemon occupies a prominent place in Zulu, Sotho, and broader southern African traditional medicine, where its common name Isihlahla (Zulu for 'tree') reflects its status as a generically recognized medicinal plant of significance. Healers have historically used bark preparations for the treatment of infections, ear ailments, arthritis, and inflammatory pain, while the bright red seeds — sometimes called lucky beans — have been worn as decorative talismans and used in divination and protective rituals across multiple ethnic groups. The tree is also culturally significant as a shade and boundary tree in homesteads, and its spectacular crimson flowers are associated with seasonal agricultural markers in parts of Zimbabwe and Mozambique. The species' use in managing thrombotic conditions and as an analgesic reflects a sophisticated empirical knowledge system that predates modern pharmacological validation, and contemporary phytochemical studies have partially corroborated its antimicrobial and anti-inflammatory applications.”Traditional Medicine
Scientific Research
The scientific evidence base for Erythrina lysistemon is limited to in vitro bioassays and a small number of preliminary in vivo animal studies, with no published human clinical trials identified in the peer-reviewed literature as of the research date. Antibacterial data are derived from MIC determinations against standard bacterial strains using isolated pure compounds and crude DCM or methanol bark extracts, representing well-established in vitro methodology but offering no pharmacokinetic or clinical translation data. Antidiabetic activity has been assessed in animal models measuring metabolic biomarkers including serum insulin, HDL, and glycosylated hemoglobin following bark extract administration, but sample sizes, dosing regimens, and statistical rigor of these studies are not fully reported in available summaries. Antiviral and antiplasmodial data consist exclusively of EC50 and IC50 values from cell-based and biochemical assays, placing this ingredient firmly in the preclinical discovery stage with a substantial translational gap before any clinical recommendations could be made.
Preparation & Dosage
Traditional preparation
**Traditional Decoction (Bark)**
Stem bark is boiled in water to produce a decoction used topically or orally in southern African traditional medicine for infections, fever, and pain; precise volumes and concentrations are unstandardized and vary by practitioner.
**Infusion (Bark)**
Dried powdered bark may be prepared as a hot water infusion; no standardized dose or preparation ratio has been established in scientific literature.
**Dichloromethane (DCM) Extract (Research Use Only)**
Laboratory extractions using DCM yield the highest concentrations of prenylated isoflavonoids and pterocarpans (e.g., erybraedin A, cristacarpin); this form is not available commercially and is used exclusively in research settings.
**Methanol (MeOH) Extract (Research Use Only)**
Methanol extracts of bark yield a broader phytochemical profile including flavans and polar compounds; crude MeOH extract MIC against S. aureus is 125 μg/mL, indicating lower potency than DCM fractions.
**No Established Supplemental Dose**
No safe, effective, or standardized supplemental dose has been identified in clinical or preclinical literature; commercial supplement forms do not exist for this ingredient.
**Standardization**
No standardization percentages for active markers such as erybraedin A have been established or validated for quality control purposes.
**Caution**
Due to the presence of toxic alkaloids and anticoagulant compounds, any preparation of E. lysistemon for internal use carries significant risk and should not be self-administered.
Nutritional Profile
Erythrina lysistemon is not consumed as a food ingredient and has no documented macronutrient or micronutrient profile relevant to nutrition. Its pharmacological relevance is entirely phytochemical: the bark is rich in prenylated isoflavonoids (erybraedin A, eryzerin C, lysisteisoflavone, alpumisoflavone), pterocarpans (phaseollidin, cristacarpin), flavans, and abyssinone-class flavonoids, with compound concentrations varying by extraction solvent — DCM extracts favor lipophilic prenylated compounds while methanol extracts capture a broader polar fraction. Seeds and bark additionally contain Erythrina-class alkaloids (specific alkaloid identities not fully characterized for this species) and unidentified anticoagulant compounds at concentrations sufficient to produce pharmacological effects, underscoring that this is a potent phytochemical source rather than a nutritional substrate. Bioavailability of the isoflavonoid fraction has not been studied in humans, and gut microbiome metabolism, protein binding, and first-pass hepatic effects on these prenylated compounds remain entirely uncharacterized.
How It Works
Mechanism of Action
Prenylated isoflavonoids and pterocarpans from E. lysistemon exert their primary antimicrobial effects through disruption of bacterial cell membranes, with the prenyl side chains increasing lipophilicity and facilitating insertion into phospholipid bilayers, while hydroxyl groups at positions 5 and 7 of the A ring and position 4′ of the B ring enhance binding affinity, explaining the superior potency of erybraedin A against Gram-positive organisms over Gram-negative ones with outer membrane barriers. Antidiabetic mechanisms are inferred from animal metabolic indices showing recovery of pancreatic islet architecture and normalization of insulin secretion, consistent with antioxidant protection of beta cells mediated by isoflavonoid radical scavenging, though specific receptor or enzyme targets such as PPAR-γ or alpha-glucosidase inhibition have not been confirmed for this species. Anti-HIV activity of compounds such as 2′-hydroxyneobavaisoflavanone likely involves inhibition of viral replication machinery at an uncharacterized step, as EC50 data are available without identification of the specific viral enzyme or host receptor targeted. Alkaloids present in bark and seeds contribute to neuromuscular and coagulation effects by interfering with cholinergic neurotransmission and platelet aggregation pathways, consistent with reported anti-blood-clotting activity, though full pharmacological characterization of the alkaloid fraction is absent from the current literature.
Clinical Evidence
No human clinical trials have been conducted on Erythrina lysistemon or its isolated compounds for any indication, including its primary traditional uses of fever reduction and pain management. Available evidence is restricted to in vitro antimicrobial assays demonstrating MIC values in the low microgram-per-milliliter range for isolated compounds, and uncontrolled preliminary animal studies examining metabolic parameters related to diabetes, neither of which constitutes clinically actionable data. Effect sizes and confidence intervals from human populations are entirely absent, and extrapolation of in vitro MIC values or animal model outcomes to human therapeutic doses is not scientifically justified without pharmacokinetic bridging studies. The clinical significance of the reported bioactivities remains speculative, and this ingredient should be regarded as a phytochemical research subject rather than a clinically validated therapeutic agent.
Safety & Interactions
Erythrina lysistemon bark and seeds contain toxic alkaloids capable of causing neuromuscular paralysis and cardiovascular effects at higher doses, making unsupervised internal use potentially dangerous; no maximum safe dose has been established through systematic toxicity studies in humans or animals. Anticoagulant compounds identified in the plant have the potential to potentiate the effects of anticoagulant and antiplatelet drugs including warfarin, heparin, aspirin, and clopidogrel, creating a significant hemorrhagic risk if combined with these medications. The plant is contraindicated in pregnancy due to the presence of alkaloids with potential uterotonic or teratogenic activity consistent with other Erythrina species, and should not be administered to children or immunocompromised individuals without medical supervision. Individuals with bleeding disorders, those scheduled for surgery, or patients on anticoagulation therapy should avoid all preparations of this plant, and anyone considering its use for traditional medicinal purposes should consult a qualified traditional healer or medical professional familiar with its toxicity profile.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Erythrina lysistemonCommon Coral TreeLucky Bean TreeUmsinsiTransvaal Kafferboom
Frequently Asked Questions
What is Isihlahla used for in traditional African medicine?
In southern African traditional medicine, Isihlahla (Erythrina lysistemon) bark preparations are used to treat bacterial infections, fever, ear ailments, arthritis, and inflammatory pain, while the seeds are worn as protective talismans. Modern phytochemical studies have partially validated its antimicrobial use by identifying potent prenylated isoflavonoids and pterocarpans such as erybraedin A (MIC 2 μg/mL against S. aureus) in bark extracts. However, no clinical trials have confirmed efficacy or safety in human patients.
Is Erythrina lysistemon safe to use as a supplement or herbal remedy?
Erythrina lysistemon is not considered safe for unsupervised supplemental use because the bark and seeds contain toxic alkaloids with potential neuromuscular and cardiovascular effects, as well as anticoagulant compounds that can potentiate bleeding risk when combined with blood-thinning medications. No established safe dose exists in the scientific literature, and there are no commercial standardized supplement forms. It is contraindicated in pregnancy, children, and individuals on anticoagulant therapy.
What are the key bioactive compounds in Erythrina lysistemon bark?
The bark of Erythrina lysistemon contains prenylated pterocarpans (erybraedin A, phaseollidin, cristacarpin), isoflavans (eryzerin C, first reported from this species), isoflavonoids (lysisteisoflavone, alpumisoflavone, abyssinone V-4′ methyl ether), and toxic alkaloids. Erybraedin A is the most potent isolated compound, with an MIC of 2 μg/mL against Staphylococcus aureus and S. epidermidis, while eryzerin C inhibits E. coli at 5 μg/mL. These compounds are extracted most efficiently using dichloromethane solvent fractionation followed by chromatography.
Does Erythrina lysistemon have antiviral or anti-HIV activity?
Preliminary in vitro data indicate that two isoflavanone compounds isolated from Erythrina lysistemon — 5-deoxyglyasperin F and 2′-hydroxyneobavaisoflavanone — inhibit HIV with EC50 values of 11.5 μg/mL and 7.6 μg/mL respectively, placing them in a range of interest for antiviral drug discovery. These are cell-based assay results only, and the specific viral or host target (e.g., reverse transcriptase, integrase, or entry receptor) has not been identified for these compounds. No animal studies or human trials have evaluated anti-HIV efficacy or safety.
How does Erythrina lysistemon compare to conventional antibiotics in treating infections?
The isolated compound erybraedin A achieves an MIC of 2 μg/mL against S. aureus in vitro, which is comparable to some conventional antibiotic benchmarks for research screening purposes, but this cannot be translated directly to clinical equivalence. Unlike conventional antibiotics, there are no pharmacokinetic data establishing what oral dose would be needed to achieve inhibitory concentrations at an infection site in humans, and the presence of toxic alkaloids in the crude plant material creates a safety barrier to therapeutic use. Erythrina lysistemon extracts should currently be considered a source of lead compounds for pharmaceutical research rather than a clinical alternative to antibiotics.
What is the most effective form of Erythrina lysistemon for antibacterial benefits?
Bark extracts of Erythrina lysistemon contain the bioactive compound erybraedin A, a prenylated pterocarpan that demonstrates potent antibacterial activity with MIC values of 2 μg/mL against Gram-positive bacteria like S. aureus and S. epidermidis in vitro. Standardized extracts targeting the prenyl group and hydroxyl substituents at rings A and B are likely to provide more consistent antibacterial efficacy than whole plant preparations. However, bioavailability in humans and optimal dosing forms for clinical use remain understudied.
Does Erythrina lysistemon interact with antibiotic medications?
While Erythrina lysistemon exhibits in vitro antibacterial properties, there is currently insufficient clinical evidence to establish definitive interactions with conventional antibiotics in humans. The herb's prenylated pterocarpans may have different metabolic pathways than synthetic antibiotics, but concurrent use should be discussed with a healthcare provider to avoid potential additive effects or altered efficacy. No major interactions have been documented in traditional or modern use, but systematic interaction studies are lacking.
What does the research evidence show about Erythrina lysistemon's pain-relieving effectiveness?
Traditional African medicine has long used Erythrina lysistemon for pain and inflammation management, and preliminary research supports the presence of bioactive compounds with anti-inflammatory potential. However, high-quality human clinical trials demonstrating analgesic efficacy, optimal dosing, and comparative effectiveness against standard pain relief options remain limited or unavailable. Most evidence for its pain-relieving effects comes from in vitro studies and traditional use rather than robust clinical data in human populations.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w isihlahla-erythrina-lysistemon curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
